Price Chart

Profile

Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.
URL https://www.vervetx.com
Investor Relations URL https://ir.vervetx.com/
HQ State/Province Massachusetts
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Nov. 07, 2024 (est.)
Last Earnings Release Aug. 08, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.
URL https://www.vervetx.com
Investor Relations URL https://ir.vervetx.com/
HQ State/Province Massachusetts
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Nov. 07, 2024 (est.)
Last Earnings Release Aug. 08, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A